Skip to content
The Intraday Markets
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

TECH Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

TECH
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

TECH Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

TECH

$72.20
+$0.05 (0.06%)+0.06%
Open
Loading chart...
IndexN/A
Market Cap11.31B
Enterprise Value11.03B
Income$0.07B
Sales$1.22B
Employees3,100
P/E37.23
P/S9.07
P/B5.17
P/C41.86
EV/EBITDA32.11
EV/Sales6.88
EPS (ttm)1.94
Earnings2025-11-05
Gross Margin64.80%
Oper. Margin8.38%
Profit Margin6.02%
Volume1.04M
Shs Outstand0.16B
Change0.07%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTD15.12%
Perf Year-9.44%
Perf 3Y-15.06%
Perf 5Y-21.92%
Perf 10Y234.32%
IPO1989-02-09
Income Statement by fiscal year, newest to oldest
MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Revenue$1.22B$1.16B$1.14B$1.11B$931.03M$738.69M$714.01M$642.99M
Cost of Revenue$429.36M$389.33M$366.89M$349.10M$298.18M$255.50M$240.51M$210.85M
Gross Profit$790.27M$769.73M$769.82M$756.50M$632.85M$483.19M$473.49M$432.14M
Gross Margin64.80%66.41%67.72%68.42%67.97%65.41%66.31%67.21%
Operating Expenses$688.02M$563.04M$470.87M$459.91M$395.55M$325.77M$347.91M$295.96M
Operating Income$102.25M$206.69M$298.94M$296.59M$237.30M$157.42M$125.58M$136.18M
Operating Margin8.38%17.83%26.30%26.83%25.49%21.31%17.59%21.18%
Net Income$73.40M$168.10M$285.26M$272.05M$140.41M$229.30M$96.07M$125.35M
Net Margin6.02%14.50%25.10%24.61%15.08%31.04%13.46%19.49%
EPS (Basic)$0.47$1.07$1.81$1.73$0.91$1.50$0.64$0.84
EBITDA$216.88M$313.14M$457.11M$413.76M$249.87M$378.41M$211.89M$200.60M
Stock Option Compensation Expense$40.83M$38.04M$39.23M$42.18M$48.98M$32.37M$32.28M$28.24M
Price To Earnings Ratio110.4167.1844.9849.97124.2644.0082.3044.24
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market Capitalization$8.10B$11.29B$12.83B$13.59B$17.45B$10.09B$7.91B$5.54B
Balance Sheet by fiscal year, newest to oldest
MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$2.56B$2.70B$2.64B$2.29B$2.26B$2.03B$1.88B$1.59B
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$639.06M$635.02M$672.18M$593.79M$691.72M$646.40M$718.82M$514.06M
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$1.92B$2.07B$1.97B$1.70B$1.56B$1.38B$1.17B$1.08B
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$1.92B$2.07B$1.97B$1.70B$1.56B$1.38B$1.17B$1.08B
Total Liabilities & Stockholders Equity$2.56B$2.70B$2.64B$2.29B$2.26B$2.03B$1.88B$1.59B
Book Value Per Share$12.18$13.12$12.51$10.84$10.14$9.04$7.71$7.20
Tangible Book Value Per Share$3.63$3.74$3.56$2.21$0.72$0.89$-0.97$0.23
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on Assets2.87%6.22%10.81%11.86%6.20%11.31%5.10%7.87%
Return on Equity3.83%8.13%14.51%15.99%8.98%16.60%8.24%11.62%
Return on Invested Capital3.18%7.32%9.99%12.08%10.47%6.72%6.00%8.99%
Quick Ratio2.382.753.502.642.593.923.153.97
Current Ratio3.463.874.843.443.354.884.055.06
Cash Flow by fiscal year, newest to oldest
MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Net Income$73.40M$168.10M$285.26M$272.05M$140.41M$229.30M$96.07M$125.35M
Depreciation$109.90M$111.71M$107.24M$101.07M$87.75M$82.74M$78.17M$64.46M
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$287.56M$298.98M$254.39M$325.27M$352.16M$205.22M$181.62M$170.37M
Capital Expenditures$31.01M$62.88M$38.24M$44.91M$44.30M$51.74M$25.41M$20.93M
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends Paid$50.39M$50.42M$50.28M$50.19M$49.62M$48.90M$48.36M$47.97M
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref Stock$275.73M$80.04M$19.56M$160.95M$43.18M$50.11M$15.40M$0.00
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash Flow$256.55M$236.10M$216.15M$280.36M$307.86M$153.47M$156.21M$149.43M
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Jul 6 · 5:59PMHalper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc. ↗Jun 25 · 9:23PMStock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition OfferThe Motley Fool ↗May 6 · 5:35PMS&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market TodayBenzinga ↗Mar 20 · 11:00AMELISpot & FluoroSpot Assay Market Report 2026-2031: Mabtech, Oxford Immunotec Global, and Cellular Technology Dominate the LandscapeGlobeNewswire Inc. ↗Feb 4 · 11:30AMBio-Techne Declares DividendBenzinga ↗Jan 21 · 9:42AMMiddle East Exosomes Market Research Report 2025-2033: Diagnostic and Therapeutic Adoption, R&D Investment, and Liquid Biopsy Demand Drive GrowthGlobeNewswire Inc. ↗Nov 5 · 11:30AMBIO-TECHNE DECLARES DIVIDENDBenzinga ↗Sep 15 · 9:29PMMdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-TechneBenzinga ↗
Show 12 more stories↓
Sep 3 · 6:45PMBio-Techne Stock Upgraded As Analyst Flags Attractive Entry PointBenzinga ↗Aug 14 · 2:00PMRecombinant Human Hair Keratin Protein Market 2025 Trends and UpdatesGlobeNewswire Inc. ↗Aug 6 · 10:08PMBio-Techne (TECH) Q4 EPS Rises 8.2%The Motley Fool ↗Aug 6 · 10:30AMBIO-TECHNE DECLARES DIVIDENDBenzinga ↗May 7 · 10:30AMBIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAMBenzinga ↗Apr 8 · 8:48AMMinimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand WorldwideGlobeNewswire Inc. ↗Mar 12 · 3:50PMComplement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - Global Forecast to 2030GlobeNewswire Inc. ↗Feb 5 · 11:30AMBio-Techne Declares DividendBenzinga ↗Jan 24 · 9:45AMSpatial Proteomics Market Report and Competitive Landscape 2025-2030, with 10X Genomics, Bruker, Fluidigm, Akoya Biosciences, PerkinElmer, Biotechne, S2 Genomics, Seven Bridges Genomics & MoreGlobeNewswire Inc. ↗Jan 22 · 6:55PMInduced Pluripotent Stem Cells Industry Poised for 9.1% CAGR Growth by 2028GlobeNewswire Inc. ↗Jan 9 · 9:34AMSingle-use Bioprocessing Probes and Sensors Market Forecast to Reach $10.95 Billion by 2034 - pH Sensors Dominate Bioprocessing Market, While Oxygen Sensors Lead Rapid Growth in Precision Biologics MonitoringGlobeNewswire Inc. ↗Oct 29 · 5:00PMGlobal Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsightGlobeNewswire Inc. ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
Hippel James
Option
62.1K
$47.60
$3.0M
Jul 29, 26
Kelderman Kim
Option
35.0K
$47.60
$1.7M
Jul 28, 26
Bohnen Shane
Option
448
$47.60
$21K
Jul 23, 26
Crouse Steven C.
Option
600
—
—
Jun 2, 26
Kelderman Kim
F
2.3K
$62.57
$144K
Nov 3, 25

Company

CEO: Kim KeldermanEmployees: 3100www.bio-techne.com
About the company↓

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Discover more

You may be interested in
IBM

IBM Corp

$235.41

↓ 0.69%
GOOGL

Alphabet Inc

$344.80

↓ 0.40%
JPM

JPMorgan Chase & Co

$362.68

↓ 0.11%
CRM

Salesforce Inc

$197.03

↓ 2.14%
DIS

Walt Disney Co

$106.36

↑ 1.52%
AMD

Advanced Micro Devices

$506.30

↑ 4.99%
BAC

Bank of America Corp

$64.36

↑ 0.45%
ORCL

Oracle Corp

$151.94

↓ 2.71%
ADBE

Adobe Inc

$265.11

↓ 1.93%
NVDA

NVIDIA Corp

$225.34

↑ 0.06%
INTC

Intel Corp

$102.86

↓ 1.53%
AMZN

Amazon.com Inc

$263.32

↓ 0.65%
The Intraday Markets

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC

Why it moved over time

Catalyst history

2 entries
Aug 13, 2026
Earnings-0.18%

Bio-Techne reported fourth-quarter revenue that topped Wall Street estimates on stronger research and diagnostics demand, a catalyst suggesting better-than-expected sales momentum heading into the next quarter.

Key fact: Bio-Techne beat Wall Street estimates for fourth-quarter revenue due to growth in its research and diagnostics businesses.

reuters.com: Bio-Techne beats revenue estimates on research, diagnostics demand uptick↗
Aug 4, 2026
Earnings+0.07%

Bio-Techne heads into fiscal fourth-quarter earnings, with analysts expecting flat revenue and lower EPS while investors will scrutinize its about $11.3 billion acquisition as a key factor for near-term guidance and valuation.

Key fact: Analysts expect flat Q4 revenue and an EPS decline; the company's about $11.3 billion acquisition is a focal point.

globenewswire.com: CMB.TECH fleet update↗